Annual Report 2010-11
Investor Presentation
Audited Financial Results FY12
Corporate Brochure
Apply Online
About Us
Philosophy
Vision & Mission
Values
Management & Board
CMD's Message
CMD's Page
Board of Directors
Management Team
History & Milestones
Corporate Governance
Safety Excellence
Quality
Environment Sustainability
CSR Endeavours
Orchid Trust
Focus Areas
Awards & Accolades
Products
Formulations (Domestic)
Cardiovascular
Anti-Diabetic
Neuropsychiatry
Nutritional Supplements
Others
API
Cephalosporins - Orals
Cephalosporins - Injectibles
Veterinary Products
Carbapenems
Non-Antibiotics
Penicillins
R&D
Infrastructure
Capabilities
Process & Pharma Research
New Drug Discovery
Pre-clinical Research
Novel Drug Delivery Systems
Biotech Research
Intellectual Property Management
CRAMS
Infrastructure
Formulations
API
Investors
Chairman's Speech
Board of Directors
Fact Sheet
Financials
Shareholding
Downloads
Analyst Coverage
Contact
Orchid Stock Info
Listing Of Securities
Technical Chart
High/Lows
Historical Share Price
Share Price Movement
10 Years Trend
Media
News
Press Releases
Photo Gallery
Video Gallery
Subscribe Alerts
Downloads
Media Kit
Contact
Careers
Spirit of Orchid!
Our Secret Ingredients
Why become an Orchidian?
Apply Online
Worldwide Operations
Partner With Us
Partnering for Success
Want to partner with us?
Contact
Global Headquarters
API
Formulations
R&D
Home
»
Media
»
Press Releases
Media
News
Press Releases
Photo Gallery
Video Gallery
Subscribe Alerts
Downloads
Media Kit
Contact
Press Releases
Archive
Year
2012
2011
2010
Orchid Pharma registers 6% growth in FY12. Long-term supply contracts continue to add value to earnings.
Chennai, India | May 14, 2012
Orchid Pharma receives US FDA approval for Naratriptan Tabs ANDA
Chennai, India | May 02, 2012
Orchid Pharma receives US FDA approval for Olanzapine Tabs ANDA
Chennai, India | April 25, 2012
Orchid redeems Foreign Currency Convertible Bonds (FCCBs) due in February 2012
Chennai, India | February 28, 2012
Next